Product Description
A concise and helpful overview of the disease, including therapies, medications, problems, and lifestyle changes.Many helpful hints in an easy to understand format which avoids a lot of hard to understand terminology in favor of a more light-hearted approach.Includes reproducible forms and many references to other sources. ... Read more

Customer Reviews (8)

Finally...
Finally a book that helped us ACTUALLY know what this disease is all about, without the medical mumbo-jumbo

A Great Starting Point to Learn About Myeloma
As a clinician, I read this book with great interest. I have a better appreciation of what the patient and caregivers go through. I will not use medical jargon ever again. I highly recommend this book for newly diagnosed myeloma patient so they can learn the basics of myeloma disease. There are many helpful tips provided by the author to make life better while dealing with myeloma.

Depressing
I actually feel that I read a different book from the other reviewers.Although I thought that the author's intentions were good, I didn't find the book to be at all positive or uplifting. There is much more up-to-date treatment information available at the International Myeloma Foundation and other websites.There is also a great forum on the Leukemia and Lymphoma website where patients and caregivers can share their experiences and advice.

Good overview to start with
Excellent overview for newly diagnosed, but with treatment modalities, newer diagnostics and staging criteria, I find most of the best up to date and newer info from the heme/onc or websites such as IMF (international myeloma foundation) or American Cancer Society.

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
What a fantastic book!! It's pulled together all the the facts that I have read from different resources and compliled them into one simple concise and understandable context. Believe it or not I can hardly put it down. I'm ordering 2 more for relatives.
Thank you Mr. Heller ... Read more

Product Description
Whether you are a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor s and patient s views, 100 Questions & Answers About Myeloma gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a hematologist-oncologist specializing in myeloma treatment, and featuring insider advice from an actual patient, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease. ... Read more

Customer Reviews (6)

Simple reading on a complex topic.
After reading several books on this topic, this is the one for anyone trying to understand this condition.

Must have for Multiple Myeloma patients or caregivers
I purchased this book for my mother who was recently diagnosed with multiple myeloma.The format of the book (Q&A) is very easy to read but also informative.Now we all better understand what the doctors are talking about and the treatment options, side effects, etc.This is a must have for people stuggling to learn quickly about multiple myeloma.

Must have for any MM patient
Very simple, clear, written in laymen's language; a good place to begin the inevitable research.I was very considerate of buying only up-to-the-minute books, as medicine changes so quickly

100 questions & answers about Myeloma
I found this book very informative. My father was diagnosised with Multiple Myeloma and I have asomewhat better understanding about the disease. I highly reccommend it for any family member of a person with MM or the person themselves.

Title Tells All
Just like the title says: this book, intended for those (and their caregivers) newly diagnosed with myeloma, answers 100 general questions you're likely to have when confronted with this nasty blood cancer. Co-written by an oncologist and a myeloma patient. No substitute for actual treatment, to state the obvious, but a good primer that doesn't have to be read cover to cover for the informative value it provides. ... Read more

Product Description
Since the advent of novel chemotherapeutic agents in the 2000s, patients with multiple myeloma have experienced an improvement in clinical outcomes and better quality of life. However, with these new agents, patients have also experienced clinical challenges and side effects that, until now, have not been accurately described.Multiple Myeloma: A Textbook for Nurses, edited by Joseph D. Tariman, PHC, MN, APRN-BC, OCN®, is the first book on multiple myeloma written by nurses for nurses. You ll discover the meaning of multiple myeloma as well as a history of the disease, including nursing contributions to myeloma care. You ll also gain an understanding of basic anatomy and physiology, the role genetics plays in patients with this disease, and you ll look at incidence rates and risk factors related to multiple myeloma. In addition, this new book details specific information on the patients that you treat.You can find out how best to make an assessment of a patient with multiple myeleoma, including staging, diagnostic testing and procedures, and making a prognosis on a patient s future health. You can also access information on the treatment of newly diagnosed patients, both transplant-eligible and transplant-ineligible, as well as treatment on patients who have relapsed or who suffer from refractory multiple myeloma. You ll also gain specialized details on evaluating patients receiving high-dose chemotherapy with stem cell transplantation, and on managing and evaluating patients receiving novel agents. Patient education is also addressed in this new book and you can gain insight on how and what to teach to your patients with multiple myeloma. Along with education, you will learn about surviving this disease, including such issues important to the patient s quality of life, including bone health, mobility, renal function, health maintenance, and psychosocial issues. Finally, you can catch a glimpse into the future with news on promising clinical trials, cellular and molecular genetics, and advances in imaging that will impact your practice in the coming years. ... Read more

Product Description
A comprehensive Guidebook to treatment options and the latest medical advances for Multiple Myeloma.

Multiple myeloma (MM) is one of several cancers categorized as "plasma cell dyscrasias." They account for 10% of all blood system malignancies.

The immune system has several types of cells that work together to fight infection and disease. Lymphocytes are the main immune system cell types. When B-cell lymphocytes respond to an infection, they mature and change into plasma cells, which produce and release proteins called immunoglobulins (antibodies) that attack and help kill disease-causing germs.

But, when these plasma cells grow out of control, they can produce tumors that in several sites, especially in bone marrow (plasmacytomas). When these tumors grow in multiple sites, they are called multiple myeloma (MM). This cancer can produce various skeletal, blood system and kidney symptoms and is most often diagnosed during an evaluation for unrelated problems, although it can present with bone pain or a fracture.

MM is the most common primary bone cancer in adults (generally in those older than 50) with an annual U.S. incidence of 3 to 4 cases per 100,000 people. It occurs with greatest frequency in African-Americans and is very rare among Asians.

Oral or intravenous chemotherapy is the standard treatment to destroy or control myeloma cells. Radiation may also be used. The choice of regimen depends on the patient's age and kidney function, and the stage of the disease. Treatment focuses on achieving and maintaining remission and on preventing complications.

Learn more by ordering your MediFocus Guidebook on Multiple Myeloma, the most comprehensive, up-to-date source of information available. You will get answers to your questions, including:

* What are the risk factors of Multiple Myeloma?
* What standard and alternative treatment options are available?
* Where are the leading doctors, hospitals and medical centers that specialize in Multiple Myeloma research and treatment?
* What are the results of the latest clinical trials?
* Where are the support groups and additional resources in my area?
* What are the promising new treatments on the horizon?

You won't find this combination of information anywhere else. Your health matters. Don't leave it to chance. Arm yourself with the most comprehensive, up-to-date research available by ordering your MediFocus Guidebook today. ... Read more

Product Description
The second issue of Emerging Cancer Therapeutics focuses on multiple myelomas also known as plasma cell myeloma, Kahler's Disease and myelomatosis. It is estimated that over 20,000 new cases are diagnosed each year with over 10,000 people dying from these malignancies. Multiple myelomas are highly treatable but rarely curable. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management.

Management options and outcomes for individuals with multiple myelomas improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation. With the increased number of therapeutic options to choose from, the clinician is better placed to offer effective therapy nut at the same time is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the treatment options today and in the future. Multiple Myeloma provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data and offers evidence-based recommendations. Written by leaders in their fields, chapters update the epidemiology of multiple myeloma, genetic abnormalities in myeloma, MGUS, Initial therapy, the role of stem transplantation, risk factors and management. ... Read more

Product Description

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.

Moving from the bench to the bedside to the forefront of therapeutic development, this source:

Product Description
Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. This book is aimed at the practitioner who is looking to put these advances into clinical context. It will serve as an up-to-date resource for treatment of myeloma and related disorders. Chapters are written by international authorities and contain color photos, diagrams, and algorithms outlining preferred treatment strategies. Relevant scientific information is integrated throughout, but the focus here is on providing practical therapeutic guidance for oncologists and hematologists caring for myeloma patients. The book covers all myeloma subtypes and related disorders, including amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, MGUS, and POEMS syndrome. ... Read more

Product Description
Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents. ... Read more

Product Description
There have been large increases in the incidence of multiple myeloma over the past thirty years, especially with regard to older individuals and blacks. The most striking epidemiologic finding is the two-fold higher incidence in blacks compared to whites. Among hematopoietic malignancies, multiple myeloma is the only one with increased incidence and mortality rates among blacks. In a workshop sponsored by the National Cancer Institute in March last year, the epidemiology of multiple myeloma was covered in depth. The papers included in this volume address differences in immunologic factors and in risk factors for multiple myeloma between blacks and whites, describe the monoclonal gammopathies and their progression to myeloma, and speculate on hypotheses regarding the etiology and pathogenesis of this challenging malignancy. Ques- tions that are addressed include whether neoplastic change occurs at the level of the plasma cell or earlier in the B-cell lineage, the role of inappropriate gene expression, the importance of IL-6 production, and new findings regarding the cytogenetics of this malignancy. Key directions for new research on multiple myeloma and related malignancies are suggested. ... Read more

Product Description

This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders.

Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies

Chapters are uniformly organized for easy data access

All authors are important authorities in their field with extensive clinical experience

Product Description
Myeloma: Biology and Management, 3/e, useful to both scientist and clinician, provides up-to-date information on the biology of the disease, along with new management and therapeutic options. Significant advances have been made in multiple myeloma over the last decade. With this increasing knowledge of the biologic mechanisms of myeloma, the third edition contains the most recent breakthroughs in treatment, including various new drugs of proven efficacy. ... Read more

Customer Reviews (1)

Excellent Myeloma Reference source
Myeloma is a very difficult and deadly sickness with no cure. Many people are misdiagnosed for years. This Handbook expands on what the IMF says in their booklet so extensively that I recommend it highly as an educationaleven though technical tool. Great job by Oxford Press and my only regret isthat there is no simple way to update it more often. So far there were 1995and 1998 editions, I look forward to the 2001 edition which could mean anoverhaul of the themes. A few non focus subjects on the sickness could beeliminated. ... Read more

Product Description
The book deals with the evaluation of high-dose chemotherapyfollowed byautologous bone marrow or blood stem cell trans-plantation as treatment forHodgkin's disease, non-Hodgkin'slymphoma and multiple myeloma. Alternative salvages strate-gies in this rapidly developing field are reviewed and riskfactors associated with clinical outcome of newlydiagnosedlymphomas and lymphomas in relapse are evaluated. Severalfundamental issues like detection of minimal residualdisease inbone marrow and blood, the need for bone marrowpurging and preferences ofblood stem cells to bone marroware discussed. The use of hematopoietic growth factors suchas GCSF and GMCSF after bone marrow transplantation aredescribed. ... Read more

Product Description
A comprehensive collection of classic and innovative methodologies used in many laboratories for the investigation of multiple myeloma. These readily reproducible techniques range from the standard Plasma Cell Labeling Index methodology to a final chapter on making sense of microarrays, and include the full spectrum of cytogenetic and molecular diagnostic methods. The protocols follow the successful Methods in Molecular Medicine™ series format, each offering step-by-step laboratory instructions, an introduction outlining the principle behind the technique, lists of the necessary equipment and reagents, and tips on troubleshooting and avoiding known pitfalls. These proven techniques are ideal for studying the pathogenesis of multiple myeloma and identifying new therapeutic targets. ... Read more

Product Description
Multiple myeloma has been one of the most studied malignancies since its discovery in the mid-nineteenth century. During the last decade, knowledge about the disease has advanced rapidly. Modern techniques have, for the first time, allowed real improvement both in understanding of the disease's pathogenesis and in clinical diagnosis and management, so that primary patients with advanced disease now have a greatly enhanced chance of survival. This book sets out, clearly and logically, the current options for clinical practice.

Multiple Myeloma provides a comprehensive and authoritative account of the condition emphasizing current diagnosis and management. The book examines the impact that new sophisticated techniques (such as immunophenotyping, cell sorting, cytogenetics, growth-factor analysis, and molecular biology) have had on our understanding of the disease. New treatment methods have not been introduced without difficutlies, and the risk factors of intensive antibacterial and antiviral therapies and transplantation are fully discussed. The contributors are all recognized experts in the field with "hands on" experience, making this invaluable reading for oncologists and hematologists. ... Read more

Product Description
This econometric study covers the latent demand outlook for multiple myeloma therapeutics across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,000 cities in Japan. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each prefecture and city, latent demand estimates are created for multiple myeloma therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in Japan). This study gives, however, my estimates for the latent demand, or the P.I.E., for multiple myeloma therapeutics in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. ... Read more

Product Description
This econometric study covers the outlook for multiple myeloma therapeutics in Asia. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries in Asia). This study gives, however, my estimates for the latent demand, or the P.I.E. for multiple myeloma therapeutics in Asia. It also shows how the P.I.E. is divided across the national markets of Asia. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business. ... Read more

Product Description
This econometric study covers the outlook for multiple myeloma therapeutics in Africa. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries in Africa). This study gives, however, my estimates for the latent demand, or the P.I.E. for multiple myeloma therapeutics in Africa. It also shows how the P.I.E. is divided across the national markets of Africa. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business. ... Read more

Product Description
Human plasmacytoma is one of the rare cancers in which an essential tumoural growth factor, interleukin-6, has been identified in vivo. The overproduction of interleukin 6 in this disease can explain the major clinical abnormalities. This text reviews recent findings concerning cytokines, cytokine receptors and the oncogenes involved in plasmacytomas. It also discusses new therapeutical approaches that have emerged from biological discoveries. ... Read more